WASHINGTON--(BUSINESS WIRE)--Targanta Therapeutics Corporation (NASDAQ: TARG) today announced that data describing oritavancin’s multiple mechanisms of action and its concentration-dependent bactericidal activity will be delivered at the combined annual meetings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Infectious Disease Society of America (IDSA), taking place in Washington, DC, October 25-28, 2008. These presentations address the mechanisms that enable oritavancin to be active against gram-positive pathogens as shown in two Phase 3 trials, both of which met their primary endpoints.
